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Atherosclerotic cardiovascular disease remains globally 
the main cause of death and morbidity[1]. The 
underlying mechanism of atherogenesis is 
multifactorial, involving functional changes of vascular 
cells including endothelial cells, smooth muscle cells, 
adventitial, and perivascular cells, and circulating cells 
including platelets and inflammatory cells[2]. Clinical 
studies demonstrate that endothelial dysfunction 
reflected by decreased bioavailability of endothelial 
nitric oxide (NO) derived from endothelial NO-synthase 
(eNOS) is not only associated with atherosclerosis and 
risk factors such as hypercholesterolemia, diabetes, 
advanced age, etc, but also predicts the future clinical 
outcomes of patients[3]. The firm evidence for the role 
of eNOS in anti-atherogenesis stems from early 
experimental studies demonstrating accelerated 
atherosclerosis in ApoE
-/-/eNOS
-/- double knockout mice 
compared to ApoE
-/- mice[4]. Endothelial dysfunction is 
therefore widely accepted as a fundamental 
pathophysiological mechanism linking various 
cardiovascular risk factors to atherosclerosis. The 
dysfunctional endothelial cells express elevated 
adhesion molecules such as VCAM-1 and ICAM-1, 
thereby promoting monocyte-endothelial interaction 
subsequently transmigration into the intima, where the 
monocytes mature to macrophages, take up lipids, 
become foam cells, leading to atheroma plaque 
formation [5].  
 
It is of note that at early to middle stages of 
atherosclerosis and advanced age, eNOS protein level in 
the vasculature is not decreased and even up-
regulated[6,7]. Much effort in the past has therefore 
been made to investigate mechanisms that regulate NO 
bioavailability at the eNOS enzymatic level. Among 
other mechanisms, an imbalance between eNOS activity  
 
 
                                                        Commentary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and oxidative stress seems critical for endothelial 
dysfunction under the conditions [8]. Alone this line, 
strategies designed to inhibit oxidative stress or to 
enhance eNOS enzyme activity are considered 
promising therapeutic possibilities for prevention and/or 
treatment of atherosclerosis. One of the targets which 
fulfils the therapeutic purpose is the NAD
+-dependent 
histone deacetylase sirtuin-1 (silent mating type 
information regulation 2 homolog, SIRT1), whose 
activation has been shown to exert numerous beneficial 
effects in many aspects including life-span expansion, 
inhibition of endothelial senescence, inflammation, 
oxidative stress, and beneficial regulation of 
carbohydrate and lipid metabolism[9].  
 
Most recent studies demonstrate that SIRT1 interacts 
directly with eNOS, causes deacetylation of the enzyme 
at lysines 496 and 506 and posttranslationally enhances 
eNOS activity[10, 11]. The relationship between 
SIRT1-eNOS signaling and atherosclerosis has been 
implicated recently by Chen and colleagues[11], who 
show that SIRT1 level is higher in descending thoracic 
aortas (atherosclerotic resistant region) than aortic 
arches (atherosclerotic prone region) of C57BL6 mice. 
Importantly, another study by Zhang and colleagues 
demonstrate that endothelial specific over-expression of 
SIRT1 decreases atherosclerosis in ApoE
-/-  mice[12]. 
The present study by Stein and colleagues[13] take 
further the “loss-of-function” experimental approach by 
using  SIRT1
+/-/ApoE
-/- mice to determine the role of 
endogenous SIRT1 on atherogenesis and endothelial 
function. They show in a recently published study 
reduced atherosclerotic lesion formation and inhibition 
of foam cell formation in SIRT1
+/-/ApoE
-/- mice as 
compared to control ApoE
-/- mice[14], confirming the 
atheroprotective role of SIRT1. In the current study, the 
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pronounced plaque ICAM-1 and VCAM-1 levels in 
SIRT1
+/-/ApoE
-/- mice and endothelial expression of 
ICAM-1 and VCAM-1 upon in vivo challenge with 
lipopolysaccharide to induce systemic inflammation. 
The inhibitory role of SIRT1 in endothelial 
inflammatory responses is further confirmed in cultured 
human aortic endothelial cells in response to TNF-α. 
An increase in reactive oxygen species (ROS) in cells in 
which  SIRT1 is silenced by siRNA has been also 
demonstrated. The results support the findings by 
various studies demonstrating anti-inflammatory and 
anti-oxidative effects of SIRT1 in endothelial cells. 
Surprisingly, no difference in endothelium-dependent 
relaxations and eNOS-S1177 phosphorylation, an 
activating mechanism of the enzyme between SIRT1
+/-
/ApoE
-/- and ApoE
-/- mice is observed. It seems that 
there is discrepancy between this study and the study by 
Zhang, et al[12] who report improved endothelium-
dependent relaxations in endothelial specific SIRT1 
transgenic mice. The discrepancy may be explained by 
different experimental conditions between the two 
studies. In the study by Zhang, endothelial function is 
investigated in wild type and endothelial specific SIRT1 
transgenic mice fed high-fat-diet (HFD) for a relatively 
longer period i.e. 6 months, while the atherosclerotic 
burden, unfortunately not the endothelial function, is 
studied in ApoE
-/- and ApoE
-/- endothelial SIRT1 
transgenic mice on HFD for 10 weeks, a protocol which 
is similar to that used in the study by Stein. It seems that 
the food utilized in the two studies is also different. 
Moreover, the protection of endothelial function 
observed in the study by Zhang could be due to an over-
expression of the transgene SIRT1 which may exert 
much stronger effect than single SIRT1 allele deletion 
model used in the study by Stein. Another possible 
explanation could be that the whole body single allele 
deletion of SIRT1 may readily affect other cell functions 
such as monocytes/macrophages as demonstrated by the 
authors in the same series of study [14], but may not be 
sufficient to affect eNOS activity. This concern could 
be addressed by determining whether eNOS acetylation 
level is indeed altered by single allele deletion of SIRT1 
in their mouse model in the future experiments. 
Nevertheless, the study by Stein and colleagues 
certainly further supports the hypothesis that SIRT1 
may be a promising therapeutic target to prevent or treat 
atherosclerosis. 
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